Effects of Pneumococcal Conjugate Vaccine 2 Years after Its Introduction, the Netherlands

Rodenburg, Gerwin D.; de Greeff, Sabine C.; Jansen, Angelique G.C.S.; de Melker, Hester E.; Schouls, Leo M.; Hak, Eelko; Spanjaard, Lodewijk; Sanders, Elisabeth A.M.; van der Ende, Arie

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Effects of Pneumococcal Conjugate Vaccine 2 Years after Its Introduction, the Netherlands

Published Date:

May 2010

Source:

Emerg Infect Dis. 16(5):816-823.

[PDF-271.87 KB]

Details:

Personal Authors:

Rodenburg, Gerwin D. ; de Greeff, Sabine C. ; Jansen, Angelique G.C.S. ; de Melker, Hester E. ; Schouls, Leo M. ; ... More ▼

Keywords:

[+]

Description:

In the Netherlands, the 7-valent pneumococcal conjugate vaccine (PCV-7) was implemented in a 3+1-dose schedule in the national immunization program for infants born after April 1, 2006. To assess the vaccine's effectiveness, we compared disease incidence before and after vaccine implementation (June 2004-June 2006 and June 2006-June 2008, respectively). We serotyped 2,552 invasive pneumococcal isolates from throughout the Netherlands, covering 25% of the country's population. Clinical characteristics were extracted from hospital records. After June 2006, vaccine-serotype invasive pneumococcal disease (IPD) decreased 90% (95% confidence interval [CI] 68%-97%) in children age eligible for PCV-7; simultaneously, however, non-vaccine-serotype IPD increased by 71% (not significant), resulting in a 44% total net IPD reduction (95% CI 7%-66%). IPD rates did not change for other age groups. In the Netherlands, PCV-7 offered high protection against vaccine-serotype IPD in vaccinated children, but increases of non-vaccine-serotype IPD reduced net vaccine benefits.

Document Type:

Journal Article

Collection(s):

Emerging Infectious Diseases

Supporting Files:

	09-1223-F5.gif	image/gif
	09-1223-F5.jpg	image/jpeg
	09-1223_finalR.nxml	text/plain
	license.txt	text/plain
	09-1223-F1.gif	image/gif
	09-1223-F1.jpg	image/jpeg
	09-1223-F2.gif	image/gif
	09-1223-F2.jpg	image/jpeg
	09-1223-F3.gif	image/gif
	09-1223-F3.jpg	image/jpeg
	09-1223-F4.gif	image/gif
	09-1223-F4.jpg	image/jpeg

No Related Documents.

You May Also Like:

Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands

Personal Author:

Knol, Mirjam J.; Wagenvoort, Gertjan H.J.; Sanders, Elisabeth A.M.; Elberse, Karin; Vlaminckx, Bart J.; de Melker, Hester E.; van der Ende, Arie;

Published:

Nov 2015

Source:

Emerg Infect Dis. 21(11):2040-2044.

Description:

Three years after a 7-valent pneumococcal conjugate vaccine was replaced by a 10-valent pneumococcal conjugate vaccine in the Netherlands, we observed a decrease in incidence of invasive pneumococcal disease caused by Streptococcus pneumoniae serotyp...

File Type:

[PDF - 1.21 MB]
Invasive Pneumococcal Disease and 7-Valent Pneumococcal Conjugate Vaccine, the Netherlands

Personal Author:

van Deursen, Anna M.M.; van Mens, Suzan P.; Sanders, Elisabeth A.M.; Vlaminckx, Bart J.M.; de Melker, Hester E.; Schouls, Leo M.; de Greeff, Sabine C.; van der Ende, Arie;

Corporate Author:

on behalf of the Invasive Pneumococcal Disease Sentinel Surveillance Laboratory Group

Published:

Nov 2012

Source:

Emerg Infect Dis. 18(11):1729-1737.

Description:

In the Netherlands, the national immunization program includes 7-valent pneumococcal conjugate vaccine (PCV7) for all newborns born after April 1, 2006. We compared the incidence of invasive pneumococcal disease (IPD) and patient and disease characte...

File Type:

[PDF - 228.78 KB]
Carriage of Streptococcus pneumoniae 3 Years after Start of Vaccination Program, the Netherlands

Personal Author:

Spijkerman, Judith; van Gils, Elske J.M.; Veenhoven, Reinier H.; Hak, Eelko; Yzerman, F.; van der Ende, Arie; Wijmenga-Monsuur, Alienke J.; van den Dobbelsteen, Germie P.J.M.; Sanders, Elisabeth A.M.;

Published:

Apr 2011

Source:

Emerg Infect Dis. 17(4):584-591.

Description:

To evaluate the effectiveness of the 7-valent pneumococcal conjugate vaccine (PCV7) program, we conducted a cross-sectional observational study on nasopharyngeal carriage of Streptococcus pneumoniae 3 years after implementation of the program in the ...

File Type:

[PDF - 260.92 KB]
Seven-Valent Pneumococcal Conjugate Vaccine and Nasopharyngeal Microbiota in Healthy Children

Personal Author:

Biesbroek, Giske; Wang, Xinhui; Keijser, Bart J.F.; Eijkemans, Rene M.J.; Trzciński, Krzysztof; Rots, Nynke Y.; Veenhoven, Reinier H.; Sanders, Elisabeth A.M.; Bogaert, Debby;

Published:

Feb 2014

Source:

Emerg Infect Dis. 20(2):201-210.

Description:

Seven-valent pneumococcal conjugate vaccine (PCV-7) is effective against vaccine serotype disease and carriage. Nevertheless, shifts in colonization and disease toward nonvaccine serotypes and other potential pathogens have been described. To underst...

File Type:

[PDF - 821.56 KB]
Systematic Review of the Indirect Effect of Pneumococcal Conjugate Vaccine Dosing Schedules on Pneumococcal Disease and Colonization

Personal Author:

Loo, Jennifer D.; Conklin, Laura; Fleming-Dutra, Katherine E.; Knoll, Maria Deloria; Park, Daniel E.; Kirk, Jennifer; Goldblatt, David; O’Brien, Katherine L.; Whitney, Cynthia G.;

Published:

Jan 2014

Source:

Pediatr Infect Dis J. 2014; 33(Suppl 2 Optimum Dosing of Pneumococcal Conjugate Vaccine For Infants 0 A Landscape Analysis of Evidence Supportin g Different Schedules):S161-S171.

Description:

Background: : To aid decision making for pneumococcal conjugate vaccine (PCV) use in infant national immunization programs, we summarized the indirect effects of PCV on clinical outcomes among nontargeted age groups. : Methods: : We systematically re...

File Type:

[PDF - 1.39 MB]